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Evaluation of Adherence to FDA Boxed Warnings
and Reimbursement Guidelines for Erythropoiesis
Stimulating Agents: Medication Use Evaluation
By: John Bossaer, PharmD; Brie Dunn, PharmD; Libby Hinds, PharmD;
James New, PharmD; Amanda Schutt, PharmD;
Lynn Uber, PharmD; Kelli Garrison, PharmD, BCPS

In December 2004, the first of
several FDA mandated boxed
warnings and labeling changes
to the erythropoiesis stimulating
agents (ESAs), darbepoetin alfa
(Aranesp®) and epoetin alfa
(Procrit®, Epogen®), emerged.
The purpose was to warn
prescribers of the potential lifethreatening adverse effects and
death in patients with cancer and
chronic renal failure (CRF)
when treated to near normal
hemoglobin (Hb) concentrations.
Reimbursement guidelines have
also changed in accordance
with these boxed warnings.
These updates have forced
institutions to re-examine ESA
prescribing practices to continue
to optimize patient safety and
reimbursement.

need for antihypertensive
medications, risk of seizures,
and pure red cell aplasia.
Dosing recommendations include
individualizing regimens to keep
the Hb between 10 and 12 g/dL.1,2
Findings in the CHOIR and
CREATE studies support the
aforementioned warnings. In these
studies, higher target Hb
concentrations (13.5 and 13 to 15
g/dL, respectively) resulted in
statistically significant increases
in composites of cardiovascular
events or death.3,4

Warnings issued for CRF focus
on lower goal Hb concentrations
when using ESAs (Table 1).
When target Hb concentrations
are higher, there has been a
noted increased risk of death and
cardiovascular events. Other
warnings include an increased

Metastatic breast cancer patients
in the BEST trial receiving ESAs
targeting Hb concentrations of 12
to 14 g/dL experienced decreased
overall survival at 1 year
compared with placebo.5 The
ENHANCE study investigated the
effects of ESA therapy compared

Warnings issued for cancer
patients were a result of decreased
survival and/or increased risk of
tumor progression (Table 1).
These warnings were based on
several post-marketing studies.
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Table 1. Appropriate ESA Administration
Boxed Warnings
Cancer
▪ ESA shortened overall survival and/or increased the
risk of tumor progression or recurrence in clinical
studies in patients with breast, non-small cell lung,
head, neck, lymphoid, and cervical cancer
▪ To decrease these risks, as well as the risk of
serious cardio- and thrombovascular events, use
the lowest dose needed to avoid RBC transfusion**
▪ Use ESAs only for treatment of anemia due to
concomitant myelosuppressive chemotherapy
▪ ESAs are not intended for patients receiving
myelosuppressive therapy when the anticipated
outcome is cure
▪ Discontinue following the completion of
chemotherapy course

CMS NCD Guidelines
Covered Indications – Cancer
▪ Hb concentration prior to ESA initiation <10 g/dL
▪ Initial dose is the recommended FDA label starting dose or
equivalent doses over other approved time periods.
− Epoetin: 150 units/kg, 3 times weekly or 40,000 units weekly
− Darbepoetin: 2.25 mcg/kg/wk or ≤ 500 mcg every 3 weeks
▪ Hb concentration remains < 10 g/dL in 4 weeks after initiation of
therapy and rise in Hb is ≥ 1 g/dL with no adjustment
▪ Hb rate of rise > 2 g/dL in 4 weeks with dose adjustment
▪ Hb rate of rise > 1 g/dL in 2 weeks with dose adjustment
▪ Chemotherapy given < 8 weeks prior

Non-covered Indications – Cancer
▪ Anemia due to folate, B12, or iron deficiency; hemolysis; bleeding;
or bone marrow fibrosis
▪ Anemia associated with the treatment of CML and AML or
Renal Failure
erythroid cancers
▪ Patients experienced greater risk for death and
▪
Anemia of cancer not related to cancer treatment
serious cardiovascular events when administered
▪ Any anemia associated only with radiotherapy
ESAs to target higher versus lower Hb concentrations
(13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in 2 clinical
▪ Prophylactic use to prevent chemotherapy-induced anemia
studies**
▪ Prophylactic use to reduce tumor hypoxia
▪ Individualize dose to achieve and maintain Hb concen- ▪ Patients with erythropoietin-type resistance due to
trations within the range of 10 to 12 g/dL**
neutralizing antibodies
▪
Anemia due to cancer treatment if patients have
Perisurgery
uncontrolled hypertension
▪ DVT prophylaxis is strongly recommended for those
receiving ESAs (EPOGEN and PROCRIT only)
pre-operatively to avoid blood transfusions
**To assess individualized dosing for cancer and CRF, the FDA-approved dosing guidelines were used.
Abbreviations: ESA - erythropoiesis stimulating agent; RBC - red blood cell; CMS - Center for Medicare and Medicaid Services;
NCD - National Coverage Determination; Hb - hemoglobin; DVT - deep vein thrombosis; CML - chronic myelogenous leukemia; AML - acute myelogenous leukemia

with placebo in patients receiving
radiotherapy for head and neck
cancer. Patients receiving ESAs
were dosed targeting a goal Hb
concentration of 14.5 and 15 g/dL
in women and men, respectively.
The primary outcome of
locoregional progression-free
survival was statistically
significant for the patients receving placebo.6 The EPO-CAN20 study examined quality of life
(QOL) as its primary endpoint in
non-small cell lung cancer
(NSCLC) patients who were not
candidates for curative treatment.
A goal Hb concentration of 12 to
14 g/dL was used. An unplanned
safety analysis (based on reports

of thrombotic events in other
trials) revealed a significant
difference in overall survival
favoring placebo.7

myelodysplasia (MDS) due to
improvements in QOL surveys,
despite a lack of survival
benefit.12

In accordance with the boxed
warnings, the American Society
of Clinical Oncology (ASCO)
recommends ESA therapy for
anemia of chemotherapy in
patients with Hb concentrations
approaching or below 10 g/dL to
avoid RBC transfusion.11 These
recommendations are based on
emerging evidence questioning
the safety of ESAs and the lack
of a survival benefit with
ESA use. The guidelines do
support ESA use in low risk

Also in correlation with the
aforementioned clinical evidence,
the Center for Medicare and
Medicaid Services (CMS)
implemented a National Coverage
Determination (NCD) for the use
of ESAs in cancer and other
neoplastic conditions in July
2007.13-14 The NCD specifies the
conditions for which ESA
treatment will be reimbursed.
These recommendations are also
listed in Table 1.
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v e i n t h r o mb o s i s ( D V T ) ,
Methods
A retrospective chart review of
pulmonary embolism (PE), or
cerebrovascular accident (CVA)
patients receiving ESAs from July
2007 through September 2008 in
were documented as having an
adverse event.
ambulatory clinics were evaluated
for adherence to boxed warnings
R e i m b u r s e me n t d a t a f o r
and CMS NCD guidelines. Any
outpatient clinic use of ESAs
ambulatory care patient who was
was collected in order to
billed for darbepoetin alfa or
evaluate average collection rates
epoetin alfa was identified from
the pharmacy order entry system. Table 2. Patient Demographics (N = 306)
The primary outcome was defined
as adherence to boxed warnings
and CMS NCD guidelines.
Secondary outcomes included
incidence of adverse clinical
outcomes and assessment of
potential revenue losses.
Patient-specific data collected
included demographics, insurance
provider, and reimbursement data.
For each dose of ESA given, data
were gathered about the
prescribing service, indication for
ESA, and number of doses
administered. Clinical outcomes
data collected included all Hb
concentrations during the
specified time frame,
appropriateness of initial dose and
subsequent dosing adjustments,
and adverse events.
Initial dosing and adjustments
were deemed appropriate based
on standards set forth by FDA
boxed warnings,1,2 FDA-approved
product labeling, and CMS NCD
guidelines.13 Indications for ESAs
other than those listed in Table 1
were also recorded to assess
usage. Average doses of ESAs
and Hb concentrations were
calculated as well.
Patients admitted to the hospital
with a recent diagnosis of an acute
myocardial infarction (AMI), deep

Age
Average (years)
59 ± 14
Race
African American
156 (51%)
Caucasian
135 (44%)
Other
15 (5%)
Sex
Female
183 (60%)
Male
123 (40%)
Prescribed ESA
Darbepoetin alfa
227 (74%)
Epoetin alfa
76 (25%)
Both
3 (1%)
Average Number of Injections per Patient
Darbepoetin alfa
3.7 ± 4.6
Epoetin alfa
2.5 ± 5.4
Indication
Anemia of CRF
151 (49.3%)
Anemia in cancer
126 (41.2%)
Perisurgery
1 (0.3%)
Other
28 (9.2%)
Prescribing Service
Nephrology
105 (34%)
Hematology/Oncology
102 (33%)
Infectious Disease
3 (1%)
Internal Medicine
35 (12%)
Transplant
49 (16%)
Gynecology/Oncology
12 (4%)
Weight
Average (kg)
79.7 ± 21.6
Average Dose
Darbepoetin alfa (mcg)
205 ± 131
Epoetin alfa (units)
27,944 ± 14,892
Hemoglobin
Average (g/dL)
9.7 ± 1.1
Funding
Medicare
137 (45%)
Medicaid
30 (10%)
Private
101 (33%)
Other
7 (2%)
Unfunded
31 (10%)

according to differing insurance
payors and indication. Average
collection rates were determined
by the percent of charges and
total reimbursement (drug
charge / total charges x total
reimbursement = drug
reimbursement). Total profit per
payor was also analyzed by
subtracting drug cost from drug
reimbursement. This review
was approved by the MUSC
institutional review board.
Data Analysis
A total of 306 patients were
included in the analysis.
Patient demographics are
listed in Tables 2 and 3.
Nephrology (34%, n = 105)
and hematology/oncology
(33%, n = 102) were the
most common services that
prescribed ESAs. Likewise
the most common indications
for ESAs were anemia of
CRF (49%, n = 151) and
anemia in cancer (41%, n =
126). Darbepoetin was prescribed more frequently
compared with epoetin (74
vs. 25%, 1% were prescribed
both). The average number
of injections, doses, and Hb
concentrations are seen in
Tables 2 and 3. Racial
demographics differed by
indication (Table 3).
Twenty-nine patients were
prescribed ESAs for
indications other than CRF
or cancer. The “other”
category included patients
with HIV, anemia of chronic
disease, myelodysplastic
disorder and perisurgery.
One patient was prescribed
an ESA for perisurgery and
the indication was deemed
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inappropriate according to the
boxed warnings.
As expected, the average doses
prescribed for anemia in cancer
were higher than those used for
anemia of CRF. However, the
average Hb for patients with
anemia of CRF was significantly
higher than patients with anemia
in cancer (9.96 ± 1.2 vs. 9.6 ± 0.8
g/dL, p = 0.0033).
Significant differences were also
found in regards to insurance data.
More patients with anemia of
CRF were covered by Medicare
(56%) compared with patients
with anemia in cancer (30%), (p
= 0.001). Also, fewer patients
with anemia of CRF compared
with cancer were unfunded (5 vs.
15 %, respectively).
Overall, adherence to boxed
warnings was met in 62% of cases
in the CRF and cancer populations
(other indications were not
included in analysis of adherence)
(Table 4). Appropriateness did not
differ significantly after analysis
by indication. A trend was noted
for boxed warning adherence after
analysis by date. Adherence was
48% in 2007 compared with 76%
in 2008 (Table 5). The most

common reasons for nonadherence in the CRF population
were Hb concentrations not
being checked every 4 to 6
weeks and doses not being
adjusted to maintain Hb concen-

trations between 10 and 12 g/dL
(Table 6). The primary reason
for non-adherence in the cancer
population was initiation of ESA
or administration of maintenance
dose when Hb was > 10 g/dL.

Table 3. Patient Demographics by Indication
CRF
N = 151
Age
Average (years)
58.6 ± 16
Race
African American
93 (62%)
Caucasian
56 (37%)
Other
2 (1%)
Sex
Female
85 (56%)
Male
66 (44%)
Prescribed ESA
Darbepoetin alfa
100 (66%)
Epoetin alfa
49 (33%)
Both
2 (1%)
Average Number of Injections per Patient
Darbepoetin alfa
5.8 ± 6.1
Epoetin alfa
1.6 ± 1.9
Weight
Average (kg)
84.5 ± 22.6
Average Dose
Darbepoetin alfa (mcg)
82 ± 42
Epoetin alfa (units)
22,072 ± 8,848
Hemoglobin
Average (g/dL)
9.96 ± 1.2
Insurance Provider
Medicare
85 (56%)
Medicaid
15 (10%)
Private
42 (28%)
Other
2 (1%)
Unfunded
7 (5%)

Table 4. Appropriateness by Indication
CRF and Cancer Indications
Boxed
CMS
Warning
Guidelines
n=277
n=127*
Appropriate
62%
48%
Not appropriate
38%
52%
Adverse events (n)
2.9% (8)

CRF Indication
Boxed
CMS
Warning
Guidelines
n=151
n=151
61%
N/A
39%
N/A
0%

Cancer
N = 126

Other
N = 29

59.2 ± 12.6

59.3 ± 13.5

48 (38%)
67 (53%)
11 (9%)

15 (52%)
12 (41%)
2 (7%)

80 (63%)
46 (37%)

18 (62%)
11 (38%)

111 (88%)
14 (11%)
1 (1%)

16 (55%)
13 (45%)
0 (0%)

2 ± 1.4
3 ± 1.7

2.3 ± 2.3
5.3 ± 12.6

73.4 ± 18

82.2 ± 24.1

310 ± 83
45,667 ± 13,478

254 ± 104
30,529 ± 18,893

9.6 ± 0.8

8.8 ± 1.4

38 (30%)
13 (10%)
51 (41%)
5 (4%)
19 (15%)

14 (48%)
2 (7%)
8 (28%)
0 (0%)
5 (17%)

Cancer Indication
Boxed
CMS
Warning
Guidelines
n=126
n=126
63%
48%
37%
52%
6.3% (8)

*

One patient had a primary indication of CRF, but also was receiving chemotherapy; therefore CMS NCD guidelines were evaluated.

Table 5. 2007 and 2008 Appropriateness for CRF and Cancer Indications
2007
2008
Boxed Warning
CMS Guidelines
Boxed Warning
CMS Guidelines
n=137
n=62
n=140
n=65
Appropriate
48%
27%
76%
68%
Not appropriate
52%
73%
24%
32%
Adverse events (n)
1.5% (2)
4.3% (6)
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Adherence to CMS NCD guidelines was 48% overall. However, adherence to guidelines improved from 2007
to 2008 (27% vs. 68%, respectively, Table 5). Interestingly, this corresponded with the CMS NCD
implementation date. The most prevalent reasons for non-adherence were inappropriate initial doses and Hb
concentration not being maintained ≤ 10 g/dL (Table 6).
Lastly, of the 2.9% of patients experiencing a DVT or PE during the evaluation period, all of the adverse
events experienced were found in patients also receiving chemotherapy. When compared with 2007, the
number of reported adverse events increased from 2 to 6 in 2008.
The average collection rate of ESAs used in Medicare patients treated in the outpatient clinics was 21% of
charges. There was a similar collection rate in Medicare patients when separated by indication. Medicare
collection rates for 2007 and 2008 were similar (0.21% and 0.20%, respectively). The highest collection rates
came from private insurance payors with an average collection rate of 52% of charges for all indications. The
collection rate for Medicaid and unfunded patients was poor.
Overall, the profit margin for ESA use was $407,608.32 including all indications and all insurance payors. The
largest profits were seen with private insurance payors while there was a net loss of income from Medicaid and
unfunded patients. Of note, the Medicare profit margin for CRF was positive while the profit margin for cancer
patients was in the negative possibly due to the CMS NCD.
Conclusions
Adherence to black box warnings and the CMS NCD guidelines was suboptimal. Over the study period of July
2007 through September 2008, 62% of ESA doses for CRF and cancer were deemed appropriate per boxed
warnings and 47% were deemed in accordance with CMS guidelines. However, adherence improved
significantly from 2007 to 2008 once the CMS NCD went into effect.
While adherence rates appear to be on the rise, reimbursement opportunities still exist especially in the
Medicare and Medicaid populations. Mandating use of anemia order forms outlining boxed warnings and CMS
NCD guidelines would increase adherence and increase potential for optimal reimbursement. Another issue
noted during this project was the lack of documentation of doses given in clinic. Doses not documented will
not receive reimbursement. Use of medication templates in Practice Partner is highly recommended.
Table 6. Percentage of Inappropriate Use
Boxed Warning – CRF
Initial dose was not appropriate
Hb was not checked every 4 to 6 weeks
Doses were not adjusted to maintain Hb between 10 and 12 g/dL
There was not an appropriate intervention for Hb rise > 2 in 4 weeks, or > 1 in 2 weeks
Doses were increased more than once monthly
Boxed Warning – Cancer
ESA was not prescribed for an appropriate indication
ESA was not discontinued within 8 weeks of discontinuation of chemotherapy
ESA was not initiated when Hb was <10 g/dL
There was not an appropriate intervention for Hb rise > 2 in 4 weeks, or > 1 in 2 weeks
Hb was not maintained at a concentration to avoid RBC transfusion
CMS NCD Guidelines
Initial dose was not appropriate
Hb was not obtained within 1 week of all doses
Hb was not maintained at <10 g/dL

2007 - 2008
n=151
10.6%
21.2%
23.2%
5.3%
0.0%
n=127
5.5%
5.5%
28.3%
4.7%
3.1%
n=127
24.0%
8.7%
37.0%

2007
n=75
9.1%
28.0%
32.0%
8.0%
0.0%
n=62
4.8%
8.1%
45.2%
6.5%
3.2%
n=62
34.5%
9.7%
53.2%

2008
n=76
11.6%
14.5%
14.5%
2.6%
0.0%
n=65
6.3%
3.1%
12.5%
3.1%
3.1%
n=65
14.3%
7.7%
21.5%

Abbreviations: CRF - chronic renal failure; Hb - hemoglobin; ESA - erythropoiesis stimulating agent; RBC - red blood cell; CMS - Center for Medicare and
Medicaid Services; NCD - National Coverage Determination
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As private insurers often follow trends set forth by CMS, it is possible private insurers will begin following similar
reimbursement guidelines. Periodic monitoring of reimbursement should be performed to ensure reimbursement rates do
not decline further. Overall, a greater adherence to guidelines could potentially not only increase safety for patients being
treated with ESAs but could also increase the overall reimbursement for ESAs provided to all of our patients.
References available upon request

Incomplete Orders….Not Being Accepted As of January 4, 2010
After a recent review, it was noted that MUSC prescribers are not following our guidelines on proper medication order writing. This is a significant safety issue for our patients. Beginning January 4, 2010, orders not
written correctly will not be accepted by nursing or pharmacy staff. The prescriber will be contact regarding any incomplete so that the order can be re-written. Please refer to Policy C78: Medication Orders for the
order writing guidelines https://www.musc.edu/medcenter/policy/Med/C078.pdf.

Did You Know…
Peramivir H1N1 Emergency Use Authorization
Recently, the Commissioner of the FDA issued an Emergency Use Authorization (EUA) of the investigational intravenous (IV) antiviral medication, peramivir, for the treatment of specific adult or pediatric inpatients with suspected or
confirmed 2009 H1N1 influenza infection. Peramivir is a neuramidase inhibitor similar to oseltamivir and zanamivir.
Emergency use of this medication is restricted to adult and pediatric inpatients who require IV therapy because they are
not responding to oral or inhaled antiviral therapy or drug delivery other than IV is not feasible. Adult inpatients may
also be treated if the clinician determines IV use is clinically appropriate for other circumstances.

The following requirements for emergency use must be fulfilled when using peramivir:
− Be aware of the EUA and read the Fact Sheet for Health Care Providers (link below)
− Ensure that the Fact Sheet for Patients and Parents/Caregivers (link below) are made available to the patients or
caregivers and document in the medical record that the patient or caregiver has received the Fact Sheet, has been informed of the alternatives to peramivir therapy, and has been informed that peramivir is an unapproved drug authorized for use under an EUA
− Ensure that adverse events and medication errors associated with peramivir will be reported to the FDA’s MedWatch
program, reports of adverse events will include the words “Peramivir EUA” and peramivir request number in the
description field, and reports of adverse events will be made within 7 calendar days of the event
− Prescribe and administer peramivir only for the indications listed above
− Ensure that a patient’s creatinine clearance will be determined prior to administration of the first dose
− Ensure that any patient who has had a past severe allergic reaction to any neuramidase inhibitor will not
receive peramivir
− Only provide additional written information relating to the emergency use of peramivir to the degree that it is
consistent with the terms of the EUA
− Make records and information in connection with the EUA and the use of peramivir available at the request of the
FDA and CDC
These requirements, along with dosing, preparation, and contraindication information, are listed in the Emergency Use
Authorization of Peramivir IV Fact Sheet for Health Care Providers available on the FDA web site (link below). Formal
requests for use in specific patients must be submitted electronically through the CDC. Once the request is accepted and
processed, it is estimated to take approximately 24 hours for the product to arrive.
Use will be restricted to the approval of the Infectious Diseases or Pulmonary/Critical Care attending physicians and will
be coordinated through the Pharmacy Distribution Center’s appointed designee to ease the EUA approval process and
expedite acquisition of the medication. The physician will be required to enter specific information, including licensure
and attestantions in the approval system provided by CDC.
FDA Health Care Provider and Patient/Caregiver Information:
Emergency Use Authorization of Peramivir Fact Sheet for Patients and Parents/Caregivers
Emergency Use Authorization of Peramivir IV Fact Sheet for Health Care Providers
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FORMULARY UPDATE FOR NOVEMBER 2009
In October 2009, the Pharmacy and
Therapeutics Committee approved the
actions listed below. The changes are
considered formulary effective unless
stated otherwise.

Additions:
Basiliximab (Simulect®)
The current formulary IL-2 antagonist
daclizumab (Zenapax®) is no longer
being produced by the manufacturer.
Basiliximab has a similar mechanism
of action and is considered to be a
suitable alternative to daclizumab for
renal transplant patients. Pre-printed
order forms have been updated.
20-mg vials

Additions with Restriction:
Recombinant thrombin (Recothrom®)
This agent is a topical thrombin
product that is effective at reducing
hemostasis in patients developing postsurgical bleeding and oozing. Due to
the potential need for this product in
situations of suspected anti-thrombin
antibody coagulopathy, recombinant
thrombin was added to the formulary
with prescribing restricted to Cardiothoracic Surgery service. Bovine
thrombin (Thrombin-JMI ® ) will
remain on the formulary.
5000-IU powder for suspension

Fibrinogen concentrate
[human] (RiaSTAP®)
This agent is for treatment of acute
bleeding episodes in patients with
congenital fibrinogen deficiency
including afibrinogenemia and
hypofibrinogenemia. It will be
centralized with other high-cost
medications in the pharmacy
distribution center. This agent will be
restricted to the Hematology service
and patients with afibrinogenemia and
hypofibrino-genemia suffering from
acute bleeding episodes.
900 to 1300 mg-vials [exact potency
labeled on vial]

Trisodium citrate 4%
This concentration has been studied
as an alternative to heparin for the
storage of dialysis catheters.
However, it is not FDA approved
for this indication. Due to the low
theoretical risk from accidental
systemic administration and the
potential for maintaining catheter
patency, this agent was added to the
formulary for the storage of dialysis
catheters with prescribing restricted
to patients with contraindications to
heparin products.
250-mL bags

Addition of Restriction:
Hydroxyzine pamoate suspension
The 25-mg/mL extemporaneous
oral suspension will now be
restricted to the Pediatric Dentistry
clinic. All other uses of hydroxyzine paomate will be substituted with
hydroxyzine hydrochloride.

Automatic Therapeutic Substitution (ATS) Protocol Addition:
Hydroxyzine products
A protocol for the conversion of
hydroxyzine pamoate (Vistaril®) to
hydroxyzine hydrochloride (Atarax®)
has been approved. These salts forms
are considered equivalent. The
hydroxyzine pamoate extemporaneous
suspension will remain on formulary
restricted to the Pediatric Dentistry
clinic. The protocol is available on the
MUSC Formulary and Drug
Information Resources Web page.

Line Extensions:
▪ Mycophenolic sodium (Myfortic®)
▪
▪
▪

Change in Restrictions:
Clevidipine (Cleviprex ® ) and
Nicardipine (Cardene®)
Due to the needs of these agents in
various units, the restrictions have
been expanded with specific
monitoring parameters for use in
the following areas:
Clevidipine (Cleviprex®)
▪ Critical care areas:
ICU, OR, ED
▪ Non-critical care areas:
Interventional Radiology (to be
monitored by Anesthesia), 6
East (MUH), 9 East (MUH),
DDPCU (ART)
Nicardipine (Cardene®)
▪ Critical care areas:
ICU, OR, ED
▪ Non-critical care areas:
Labor and Delivery, 6 East
(MUH), 9 East (MUH),
DDPCU (ART)
The formulary effective date is to
be determined to allow for the updating of pre-printed forms.

▪
▪
▪

180- and 360-mg delayed-release
tablets
Aztreonam (Azactam®)
1- and 2-g/50-mL premixed bags
Benztropine (Cogentin®) 2-mg/mL
vials [generic]
Tetracaine (Pontocaine®)
2% solution [restricted to the
outpatient clinics]
Povidone-iodine (Betadine®) 5%
ophthalmic solution
[restricted to Ophthalmology]
H1N1 vaccine intranasal and
injectable products [formulary effective at first availability]
Nevirapine (Viramune®) 50-mg/mL
oral suspension

Deletions:
▪ Daclizumab (Zenapax®) 5-mg/mL
▪
▪
▪
▪
▪

injection
Dipivefrin (Propine®)
ophthalmic solution
Benztropine (Cogentin®) 2-mg/mL
ampules [brand]
Aztreonam (Azactam®) 500-mg, 1-g,
and 2-g vials
Pentazocine-naloxone (Talwin NX®)
50/0.5-mg tablets
Hydroxyzine pamoate (Vistaril®)
25- and 50-mg capsules
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FORMULARY UPDATE FOR DECEMBER 2009
In November 2009, the Pharmacy
and Therapeutics Committee approved
the actions listed below. The changes
are considered formulary effective
unless stated otherwise.

Additions with Restriction:
Plerixafor (Mozobil®)
Plerixafor is a CXCR4 antagonist used
as a stem cell mobilizing agent in patients with non-Hodgkin’s lymphoma
(HNL) and multiple myeloma (MM).
Use of this medication may entail
higher up-front cost; however, there is
a potential to improve patient quality
of care and reduce long-term institutional cost. Therefore, plerixafor was
added to the formulary with prescribing restricted to the Hematology/
Oncology service under outpatient settings. Additionally, each patient should
be evaluated for appropriate reimbursement prior to initiation of therapy.
20 mg/mL, 1.2-mL vial

Peramivir
Peramivir is a neuramidase inhibitor
similar to oseltamivir and zanamivir
that was recently granted an Emergency Use Authorization (EUA) by the
FDA for the treatment of specific adult
or pediatric inpatients with suspected
or confirmed 2009 H1N1 influenza
infection. See the page 6 more detailed
information. Due to the highly specialized acquisition, prescribing, and
monitoring process, peramivir was
added to the formulary with restrictions to attending level approval from
Infectious Diseases and Pulmonary &
Critical Care. Services requesting use
of peramivir must work with the Distribution Center to complete the online
form.
10-mg/mL vial

Change in Restrictions:

received at least 1 prior therapy.
However, newer evidence from a
series of case reports has shown
that bortezomib may also be effective in preventing antibody- and
cell-mediated acute rejection in
transplant patients. Due to this evidence, the restriction for bortezomib will be expanded to include
use by Solid Organ Transplant physicians per the Chemotherapy Prescribing Restrictions. Administration will require a chemotherapycertified nurse from 7W university
hospital.

Addition of Nonformulary
Restriction:
Domperidone maleate
Currently, domperidone does not
have FDA approval for any indication and is not commercially available for any use in the United States
because of recognized health risks.
Domperidone can ONLY be given
as part of an Investigational New
Drug (IND) application through the
FDA.
Inpatient use of a home supply of
domperidone with or without evidence of an IND will be brought
before MUSC Legal Affairs Department for recommendations on
usage allowance. Currently, use of
domperidone by inpatients of
MUSC WILL NOT be allowed
unless evidence of a current IND is
provided and the prescriber verifies
that the patient is appropriately
receiving the medication through
the FDA.

Line Extension:
▪ Calcium carbonate (Tums Ultra®)
1000-mg tablets

®

Bortezomib (Velcade )
Bortezomib is indicated for the treatment of patients with multiple myeloma and for the treatment of patients
with mantle cell lymphoma who have

Deletion:
▪ Morphine sulfate 0.2-mg/mL oral
extemporaneous suspension

Changes in Anti-retroviral
Formulary Medications
The anti-retroviral agents available on
the formulary have been modified
based on guidelines and prescribing in
the Infectious Diseases clinic.
Additions or Line extensions:
▪ Atazanavir (Reyataz®)
300-mg tablets
▪ Darunavir (Prezista®)
400- and 600-mg tablets
▪ Efavirenz (Sustiva®)
600-mg tablets
▪ Emtricitabine/tenofovir (Truvada®)
200/300-mg tablets
▪ Efavirenz/emtricitabine/ tenofovir
(Atripla®) 600/200/300-mg tablets
▪ Lamivudine (Epivir®) 300-mg tablets
▪ Lopinavir/ritonavir (Kaletra®)
100/25-mg tablets
▪ Raltegravir (Isentress®)
400-mg tablets
Deletions:
▪ Atazanavir (Reyataz®)
100- and 150-mg tablets
▪ Efavirenz (Sustiva®)
200-mg tablets
▪ Lamivudine (Epivir®)
150-mg tablets
▪ Nelfinavir (Viracept®)
250-mg tablets
▪ Didanosine (Videx® EC)
125- and 200-mg tablets
▪ Fosamprenavir (Lexiva®)
700-mg tablets
Updated Opioid Comparison/
Conversion Chart
The Chart has been revised to include
more detailed information regarding
conversion calculations, fentanyl dosing, methadone dosing, and use of
naloxone. This chart will be made
available on the Department of Pharmacy Services and Formulary and
Drug Information Resources web sites.
Pocket cards are being printed and can
be orders through the Department.

Visit the Formulary and Drug Information Resources Web page at www.formularyproductions.com/musc.

